|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 12 (June 15), 1999:
pp. 4125-4130
Cladribine Activity in Adult Langerhans-Cell Histiocytosis
Alan Saven and
Carol Burian
From the Division of Hematology/Oncology, Ida M. and Cecil H. Green
Cancer Center, Scripps Clinic, La Jolla, CA.
Langerhans-cell histiocytosis (LCH) results from the accumulation of
tissue histiocytes derived from the same progenitor cells as monocytes.
Because cladribine is potently toxic to monocytes, we conducted a phase
II trial of cladribine. Cladribine was administered to 13 LCH patients
at 0.14 mg/kg per day by 2-hour intravenous infusion for 5 consecutive
days, every 4 weeks for a maximum of six courses. Median age was 42 years (range, 19 to 72) and median pretreatment disease duration was 99 months (range, 6 to 252). One patient was untreated, one had received
prior prednisone only, one prior radiation only, six prior radiation
and chemotherapy, and four prior surgery, radiation, and chemotherapy.
Seven patients had cutaneous involvement, six multifocal osseous, six
pulmonary, two each with soft tissue and nodal involvement, and four
had diabetes insipidus. Of 13 patients, 12 were evaluable for response and all for toxicity. After a median of three courses (range, 1 to 6),
seven (58%) patients achieved complete responses (two pathologic and
five clinical) and two (17%) patients achieved partial responses;
overall response rate, 75%. Median response follow-up duration was 33 months (range, 1 to 65). Seven patients experienced grade 3 to 4 neutropenia. Only one patient had a documented infection, dermatomal
herpes zoster. At a median follow-up of 42 months (range, 5 to 76), 12 patients remain alive and one patient has died. Thus, cladribine has
major activity in adult LCH and warrants further investigation in both
pediatric and adult LCH as a single agent and in combination with other drugs.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R Lazor, B Etienne-Mastroianni, C Khouatra, A Tazi, V Cottin, and J-F Cordier
Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy
Thorax,
March 1, 2009;
64(3):
274 - 275.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Lynch III
Rare Interstitial Lung Diseases: Pulmonary Langerhans Cell Histiocytosis, Lymphangioleiomyomatosis, and Cryptogenic Organizing Pneumonia
ACCP Pulmonary Med Brd Rev,
January 1, 2009;
25(0):
585 - 618.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sanchez-Guerrero, G. Agreda, E. Oviedo, and C. Lome
Langerhans Cell Histiocytosis Responding to 2-Cda and Imatinib Mesylate (IM)
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
4649 - 4649.
[Abstract]
|
|
|
|
|
|
|
C. A. Vogel, W. Aughenbaugh, and H. Sharata
Excimer Laser as Adjuvant Therapy for Adult Cutaneous Langerhans Cell Histiocytosis
Arch Dermatol,
October 1, 2008;
144(10):
1287 - 1290.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. von Stebut, S. Schadmand-Fischer, W. Brauninger, A. Kreft, C. Doberauer, and K. Steinbrink
Successful Treatment of Adult Multisystemic Langerhans Cell Histiocytosis With Psoralen-UV-A, Prednisolone, Mercaptopurine, and Vinblastine
Arch Dermatol,
May 1, 2008;
144(5):
649 - 653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fahrner, B. Hoksch, M. Gugger, and R. A. Schmid
Langerhans cell histiocytosis as differential diagnosis of a mediastinal tumor
Eur. J. Cardiothorac. Surg.,
March 1, 2008;
33(3):
516 - 517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dewan, A. A. Al-Ghamdi, and M. B. Zahrani
Lessons to be learned Langerhans' cell histiocytosis
Perspectives in Public Health,
January 1, 2008;
128(1):
41 - 46.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. B. Green and J. N. Allen
Cough, Dyspnea, and Reticulonodular Opacities in a 58-Year-Old Smoker
Chest,
August 1, 2007;
132(2):
700 - 703.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tazi
Adult pulmonary Langerhans' cell histiocytosis.
Eur. Respir. J.,
June 1, 2006;
27(6):
1272 - 1285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rubio, V. Recasens, M. Dobon, C. Salvador, M. Giralt, and P. Giraldo
Langerhans Cells Histiocytosis: Description of 6 Cases.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
3805 - 3805.
[Abstract]
|
|
|
|
|
|
|
C Myra, L Sloper, P J Tighe, R S McIntosh, S E Stevens, R H S Gregson, M Sokal, A P Haynes, and R J Powell
Treatment of Erdheim-Chester disease with cladribine: a rational approach
Br J Ophthalmol,
June 1, 2004;
88(6):
844 - 847.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. C. Kluin-Nelemans, J. M. Oldhoff, J. J. van Doormaal, J. W. van 't Wout, G. Verhoef, W. B. J. Gerrits, O. A. van Dobbenburgh, S. G. Pasmans, and R. Fijnheer
Cladribine therapy for systemic mastocytosis
Blood,
December 15, 2003;
102(13):
4270 - 4276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pardanani, R. L. Phyliky, C.-Y. Li, and A. Tefferi
2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell Histiocytosis
Mayo Clin. Proc.,
March 1, 2003;
78(3):
301 - 306.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, C.-Y. Li, J. H. Butterfield, and H. C. Hoagland
Treatment of Systemic Mast-Cell Disease with Cladribine
N. Engl. J. Med.,
January 25, 2001;
344(4):
307 - 309.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Vassallo, J. H. Ryu, T. V. Colby, T. Hartman, and A. H. Limper
Pulmonary Langerhans'-Cell Histiocytosis
N. Engl. J. Med.,
June 29, 2000;
342(26):
1969 - 1978.
[Full Text]
[PDF]
|
|
|
|
|
